key: cord-0691818-5wry9vfc
authors: Mei, Dan; Tan, W. S. Daniel; Liao, Wupeng; Heng, C. K. Matthew; Wong, W. S. Fred
title: Activation of angiotensin II type-2 receptor protects against cigarette smoke-induced COPD
date: 2020-10-02
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.105223
sha: 3919e1d850b05ba8b102408ce0bb20d188bdf2cc
doc_id: 691818
cord_uid: 5wry9vfc

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally. Cumulative evidence has implicated renin-angiotensin system (RAS) in the pathogenesis of COPD. This study aimed to investigate potential protective effects of angiotensin II type-2 receptor (AT2R) activation in cigarette smoke (CS)-induced COPD models. Compound 21 (C21), a selective and potent non-peptide small molecule AT2R agonist, was evaluated for anti-inflammatory, anti-oxidative and anti-remodeling activities in a two-week (acute) and an eight-week (chronic) CS-induced COPD models. C21 inhibited CS-induced increases in macrophage and neutrophil counts, pro-inflammatory cytokines and oxidative damage markers in bronchoalveolar lavage (BAL) fluid, and TGF-β1 in lung tissues, from COPD models. C21 restored phosphatase activities and reduced phospho-p38 MAPK, phospho-ERK and p65 subunit of NF-κB levels in CS-exposed lung tissues. C21 also suppressed CS-induced increases in α-Sma, Mmp9, Mmp12 and hydroxyproline levels in lung tissues, and neutrophil elastase activity in BAL fluid. C21 modulated RAS in CS-exposed lungs by downregulating Ang II but upregulating Ang-(1–7) and Mas receptor levels. C21 prevented CS-induced emphysema and improved lung functions in chronic COPD model. We report here for the first time the protective effects of AT2R agonist C21 against CS-induced COPD, and provide strong evidence for further development of AT2R agonist for the treatment of COPD.

Chronic obstructive pulmonary disease (COPD) is characterized by alveolar space enlargement and airway remodeling, leading to breathlessness and impaired lung function [1] . COPD ranks third in the global leading cause of death, with 3.2 million deaths in 2017. Annual mortality from COPD is estimated to reach 4.4 million by 2040 [2] . Cigarette smoking is the major risk factor for COPD, which delivers huge amount of reactive oxygen and nitrogen species into the lungs that incite production of inflammatory cytokines like IL-1β, IL-6 and TNF-, and infiltration of inflammatory cells like macrophages and neutrophils [3, 4] . Infiltrated neutrophils and macrophages are the major sources of endogenous free radicals generated by enzymes like myeloperoxidase and NADPH oxidase [4, 5] , which accentuate excessive oxidative damage to the lungs [6, 7] . Current COPD therapeutics fail to stop the progression of the disease or reduce the mortality. Most COPD patients are also corticosteroid-insensitive [8] .

There is an urgent need to discover novel therapeutic strategies for the treatment of COPD. Renin-angiotensin system (RAS) plays a central role in regulating blood pressure and electrolyte homeostasis [9, 10] . More recently, cumulative evidence has implicated RAS in the J o u r n a l P r e -p r o o f pathogenesis of COPD [11, 12] . Renin, an endopeptidase, cleaves angiotensinogen into angiotensin I (Ang I) decapeptide which, in turns, is cleaved by angiotensin converting enzyme (ACE), a zinc metallopeptidase, into Ang II octapeptide. Ang II is subsequently cleaved by ACE2, a homologue of ACE, into Ang-(1-7) [9, 10] . Ang II can bind and activate G proteincoupled receptors (GPCRs) Ang II type-1 receptor (AT1R) and Ang II type-2 receptor (AT2R), while Ang-(1-7) binds and activates G protein-coupled Mas receptor. AT1R activation not only leads to vasoconstriction and renal retention of electrolytes and water, but also promotes inflammation, proliferation and fibrosis [11] . In contrast, activation of AT2R and Mas receptor mediates opposing effects including vasodilatory, anti-proliferative, anti-oxidative, antiinflammatory and anti-fibrotic actions [11, 12] . AT1R blockers have been shown to antagonize TGF- signaling, attenuate alveolar cell apoptosis, emphysema, metalloprotease activation and epithelial hyperplasia, and increase running distance in mouse models of COPD [13, 14] .

Population-based clinical studies have revealed that the use of AT1R blockers was associated with slower progression of percent emphysema in general population, especially in former smokers [15] , and with lower risk of pneumonia and lower mortality in COPD patients [16, 17] .

On the other hand, Ang-(1-7), by activating Mas receptors, exhibited anti-inflammatory, antioxidative and anti-fibrotic actions, restored autophagic functions, and improved locomotor activity in mouse models of COPD [18] [19] [20] . The role of AT2R in COPD is unknown. The purpose of the present study was to investigate potential protective effects of AT2R activation in cigarette smoke (CS)-induced COPD mouse models.

J o u r n a l P r e -p r o o f Compound 21 (C21) is the first non-peptide AT2R-selective small molecule agonist with an AT2R affinity constant of 4x10 -10 M and AT1R affinity constant of 1x10 -5 M, exhibiting >25,000-fold selectivity for AT2R [21, 22] . C21 contains a biaryl privileged structure with isobutyl lipophilic side chain, a sulfonylcarbamate group and a methylene imidazole moiety to induced AT2R conformational change during receptor activation (Fig. 1A ) [23] . C21 has been shown to lower infiltrated macrophages, lung inflammation, collagen deposition, muscularization of pulmonary vessels and right ventricular remodeling in a bleomycin-induced lung injury rat model [24] . C21 has been tested in a Phase I clinical trial and is confirmed to be safe and well-tolerated in humans [25] . The present study reported for the first time the benefits of AT2R activation that C21 exhibited anti-inflammatory, antioxidative, anti-remodeling and lung function restoration actions in acute and chronic CSinduced COPD models.

Female BALB/c mice of 6-8 weeks old (InVivos Pte. Ltd., Singapore) were placed in a ventilated chamber and exposed to 5% CS from 3 sticks of 3R4F research cigarettes (Tobacco and Health Research Institute, University of Kentucky, Lexington, KY) for 20 min three times daily at 2 h interval 5 days per week for 2 weeks to develop the CS-induced acute lung injury model as described [26] (Fig. 1B) . Sham air controls were mice placed in a separate ventilated weeks, and C21 (0.3 mgkg -1 ) was given once daily 1 h before CS exposure in the last three weeks as described [26] (Fig. 5A ). Mice were sacrificed 24 h after the last CS exposure for analyses. Animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee of the National University of Singapore.

Mice were anaesthetized using 400 μL of anesthetic mixture (7.5 mgmL -1 ketamine + 0.1 mgmL -1 medetomidine) by i.p. injection. Tracheotomy was performed and a cannula was inserted into the trachea. Ice cold PBS (0.5 mL × 3) was instilled into the lungs and the BAL fluid was collected for cell counts, neutrophil elastase (NE) activity and ELISA analysis.

Lung tissues were homogenized in PBS using a ceramic bead-based homogenizer (Bertin 

Lungs were fixed in 10% neutral formalin, paraffinized, cut into 5-µm sections, and stained with hematoxylin and eosin (H & E) for examining airway inflammation and scoring epithelium thickness and alveolar enlargement, performed in a blinded manner as described previously [26, 27] .

For the chronic CS exposure model, mice were anaesthetized with 150 μL of the same anesthetic mixture by i.p. injection, followed by tracheotomy as described [26] . Mice were placed in a whole-body plethysmograph connected to a computer-controlled ventilator (Forced Pulmonary Maneuver System, Buxco Research System, Wilmington, NC, USA) [26] . Lung functions were recorded using the FinePointe TM data acquisition and analysis software (Buxco Research System).

Data are presented as mean ± SEM. Significant difference between treatment groups was determined by one-way ANOVA followed by Dunnett's test. Significant level was set at p < 0.05. All statistical analyses were conducted with GraphPad Prism software. # indicates p < 0.05 when CS group compared to sham air control group; whereas, *indicates p < 0.05 when C21treated groups compared to vehicle control.

J o u r n a l P r e -p r o o f

Ang I, Ang II and Ang-(1-7) levels were significantly upregulated in the lungs in response to CS challenge. Among the doses used, C21 at 0.3 mgkg -1 could markedly revert Ang I and Ang II back to basal levels, and noticeably enhanced Ang 1-7 level (Fig. 1C ). Acute CS exposure or C21 treatment had no obvious effect on ACE, ACE2 or AT1R levels in the lungs. However, acute CS challenge slightly reduced AT2R level and evidently lowered Mas receptor level, but C21 (0.3 and 1 mgkg -1 ) restored AT2R and Mas receptor levels (Fig. 1D ).

J o u r n a l P r e -p r o o f , and up-regulation of glutathione peroxidase 2 (Gpx2), in CS-exposed lungs (Fig. 3B) . Acute CS markedly increased lung tissue levels of active TGF-β1 and of transcription factors smad2 and smad3 (Fig. 3C) , which mediate TGF- receptor signaling response [28] . C21 reduced the levels of TGF-1 and smad2/3 in a dose-dependent manner (Fig. 3C) . Correspondingly, C21 reverted acute CS-induced increase in -smooth muscle actin (-Sma) and matrix metalloproteinase 12 (Mmp12) in lung tissues (Fig. 3C ).

J o u r n a l P r e -p r o o f 

AT2R activation has been shown to activate phosphatase activities [10, 11] . CS exposure noticeably diminished total phosphatase and slightly diminished SH2-domain-containing phosphatase-2 (SHP-2) activities, and C21 regenerated phosphatase activity in the lungs (Fig.   4A ). CS challenge markedly upregulated total p38 MAPK, phospho-p38 MAPK, phospho-ERK and p65 subunit of NF-B levels in the lungs, while down-regulated total ERK level. C21

was able to repress the protein levels of total p38 MAPK, phospho-p38 MAPK, phospho-ERK and p65 subunit of NF-B to the baseline, and conversely restored total ERK level to basal level (Fig. 4B ). 

As the C21 dose of 0.3 mgkg -1 has demonstrated consistent protective effects in the acute CSinduced lung injury model, we have selected this effective dose to study potential benefits of C21 in the chronic CS-induced COPD model (Fig. 5A) . Chronic CS challenge markedly upregulated Ang I, Ang II and Ang-(1-7) levels in lung tissues. C21 differentially modulated Ang J o u r n a l P r e -p r o o f I and Ang II down to basal levels, but up Ang-(1-7) to a higher level (Fig. 5B ). Chronic CS exposure significantly increased ACE and ACE2 levels in the lungs, but C21 repressed their protein levels down to baseline controls (Fig. 5C ). Chronic CS down-regulated AT1R and Mas receptors in the lungs, but elevated AT2R level. C21 treatment was able to reverse the alterations induced by CS on these receptors to their basal levels (Fig. 5C ). 

C21 significantly inhibited the chronic CS-induced increases in BAL fluid total cell, macrophage and neutrophil counts (Fig. 6A ). In addition, C21 blocked chronic CS-induced rise in BAL fluid pro-inflammatory cytokines including TNF-, KC, IL-6 and IL-17A (Fig. 6B) .

Furthermore, C21 reduced chronic CS-induced inflammatory cell infiltration and epithelial thickening (Fig. 6C ). Chronic CS exposure markedly increased Muc5b gene expressions in lung tissues, with minor effect on Muc5ac, and C21 significantly reduced pulmonary gene expression of Muc5b (Fig. 6D ).

J o u r n a l P r e -p r o o f 

Chronic CS significantly increased lung tissue levels of active TGF-β1 and of transcription factors smad2 and smad3 (Fig. 7A) . C21 repressed the levels of TGF-1 and smad2/3 to the basal levels (Fig. 7A) . Correspondingly, C21 reverted chronic CS-induced increase in -Sma in lung tissues (Fig. 7A) . Besides, C21 significantly abated chronic CS-induced elevation of NE activity in BAL fluid, and hydroxyproline level, Mmp9 and Mmp12 gene expression in lung tissues (Fig. 7B ). Furthermore, C21 was able to augment CS-induced elevation of tissue inhibitor of metalloproteinase-1 (Timp-1) expression in lung tissues (Fig. 7B ). J o u r n a l P r e -p r o o f

Chronic CS exposure induced obvious enlargement of alveoli measured as increases in alveolar diameter, and C21 was able to significantly reduce alveolar enlargement (Fig. 8A) . Chronic CS exposure decreased forced expiratory volume in 100 ms over forced vital capacity ratio (FEV100/FVC, equivalent to FEV1/FVC ratio in humans), inspiratory capacity (IC) and dynamic compliance (Cdyn), but increased total lung capacity (TLC), functional residual capacity (FRC) and static compliance (Cchord) (Fig. 8B ). C21 significantly mitigated TLC, FRC and Cchord, and restored FEV100/FVC, IC and Cdyn in chronic CS-challenged mice.

J o u r n a l P r e -p r o o f 

In both acute and chronic CS models, Ang I and Ang II were markedly elevated in the lungs.

While Ang II can bind to AT1R and AT2R, it is the AT1R activation that causes proinflammatory, pro-oxidative and pro-fibrotic effects in COPD [11, 12] . We observed increases in macrophage and neutrophil counts, oxidative damage markers and pro-inflammatory cytokine levels in the BAL fluid, and inflammatory cell infiltration and epithelial thickness in the lung sections obtained from CS-exposed lungs. AT1R acts through coupling to Gq/11, G12/13 and Gi, and through receptor transactivation to stimulate multiple signaling processes including p38 MAPK, ERK, NF-B and NADPH oxidase pathways [10, 11] . In the acute CS model, we were able to capture heightened levels of phospho-p38 MAPK, phospho-ERK and NF-B p65 subunit in the lung tissues.

Acute CS challenge did not alter the levels of ACE, ACE2, AT1R and AT2R in the lung tissues;

however, chronic CS exposure significantly upregulated ACE, ACE2 and AT2R levels, while downregulated AT1R level in the lungs, indicative of a compensatory response to control airway inflammation. It has been shown that CS-exposed lungs expressed higher levels of ACE2 [29, 30] , implying more conversion of pro-inflammatory Ang II into anti-inflammatory Ang-(1-7) to counteract CS damage to the lungs. Lately, ACE2 has taken the center stage as the pivotal receptor for coronavirus infection (e.g. SARS-CoV-2) leading to severe acute pulmonary syndrome. COPD patients have higher levels of ACE2, implicating that they are more susceptible to SARS-CoV-2 infection [29] [30] [31] . Unexpectedly, C21 was able to lower the ACE2 back to baseline level in chronic CS-exposed lungs. Increased AT2R expression has J o u r n a l P r e -p r o o f been reported in inflammation models including idiopathic lung fibrosis [24] , rheumatoid arthritis [32] and glomerulonephritis [33] . It has been shown that activation of AT1R upregulated AT2R expression in rat aorta [34] . AT2R is an atypical GPCR that it acts through coupling to Gi/Go as well as Gs, and through activating G protein-independent pathways like serine/threonine phosphatase 2A, SHP-1 and SHP-2, resulting in anti-inflammatory, antiproliferative and anti-fibrotic effects [11, 35, 36] . In this study, AT2R activation by C21 markedly suppressed CS-induced increases in BAL fluid levels of macrophage and neutrophil counts, pro-inflammatory cytokines, and oxidative damage markers 8-OHdG and 8-isoprostane, and in inflammatory cell infiltration, epithelial thickening and muc5b expression. Besides, C21

promoted endogenous antioxidant gene expression including Ho-1, Nqo1, Gsr and Gpx2 to counteract CS-induced oxidative stress. In addition, CS exposure down-regulated phosphatase activities in lung tissues, but C21 was able to restore total phosphatase and SHP-2 activities to normal levels. As a result, we observed that C21 treatment reduced phospho-p38 MAPK and phospho-ERK levels in the CS-exposed lungs.

Both acute CS and chronic CS models markedly elevated TGF-1 levels and upregulated the lung tissue levels of transcription factors Smad2 and Smad3 which mediate TGF-1-induced signaling process [28, 37] . TGF-1 release from various cell types such as macrophages, neutrophils and epithelial cells has been shown to be AT1R-dependent [10, 11, 37] . TGF-1 is a major pro-fibrotic factor to drive airway remodeling by transdifferentiation of fibroblasts to myofibroblasts and production of extracellular cellular matrices such as collagen [37] . C21 treatment was able to block the CS-induced elevation of TGF-1 and Smad2/Smad3, and TGF-1-sensitive -Sma gene expression as well. In the chronic CS model, Mmp9, Mmp12 expression and NE activity were markedly upregulated. They are released from the macrophages and neutrophils, and act by degrading collagen and elastin leading to tissue destruction in the airways [38, 39] . C21 noticeably reduced Mmp9 and Mmp12 expression, NE activity and the level of hydroxyproline, the major breakdown product of collagen [40] .

Besides, C21 augmented the gene expression of Timp-1, a critical proteinase inhibitor of MMP9 and MMP12 [41] . In addition, it has been shown that inhibition of p38 MAPK or ERK signaling pathway could block the release of MMP9 from alveolar macrophages [41] . Another possible mechanism of action for C21 is to induce formation of AT2R and AT1R heterodimer resulting in AT1R blockade. Although AT2R per se does not undergo receptor desensitization upon Ang II activation, it promotes AT2R-AT1R heterodimer internalization to inhibit AT1R signaling [42, 43] .

In both acute and chronic mouse models, C21 markedly restored Mas receptors to normal level and augmented the level Ang-(1-7), the endogenous ligand for the Mas receptor [44] . AT2R

and Mas receptor are considered the "protective arm" of the RAS, counterbalancing the proinflammatory effects of AT1R activation as physiological antagonists [43, 45] . Mas receptor is coupled to Gq, Gi/s and G12 and is constitutively active in producing cAMP [44] . Recent study showed that Ang- (1-7) is a poor G protein activator but it may act via Mas receptors in a yet unknown effector pathway to mediate anti-inflammatory and anti-fibrotic actions [44] .

Ang-(1-7) treatment has been shown to attenuate CS-induced lung inflammation, fibrosis and oxidative damage in COPD moues models [19, 20] . In addition, Mas receptors can act by J o u r n a l P r e -p r o o f forming heterodimers with AT1R to disrupt AT1R signaling responses [45, 46] . AT2R and Mas receptor function in a strikingly similar mechanisms, and recent studies have revealed their colocalization and heterodimerization, and functional interdependence in mediating antiinflammatory actions [36, 43, 45] .

Our findings reveal for the first time the protective effects of AT2R agonist C21 against CSinduced COPD. AT2R is an attractive target for agonist-based therapeutic strategy because AT2R per se is resistant to receptor uncoupling and internalization due to fewer serine/threonine residues located in the carboxyl-terminal [46] . This property offers multiple treatment benefits including minimum dosage requirement, minimum drug tolerance development, and minimum dose-related side effects. In addition, as AT2R level is low in normal situation but highly upregulated in pathophysiological conditions such as inflammation, therapeutic efficacy of AT2R agonist is expected to be the highest during inflammatory phase, and upon resolution phase, AT2R level will decline, and as such the dose requirement and potential AT2R-related side effects will be minimized as well. The present study provides strong scientific evidence for further development of AT2R agonist, such as C21, for the treatment of COPD.

None.

J o u r n a l P r e -p r o o f

Update on the pathogenesis of chronic obstructive pulmonary disease

Update on clinical aspects of chronic obstructive pulmonary disease

Reactive oxygen species in chronic obstructive pulmonary disease

The other myeloperoxidase: Emerging functions

Oxidative stress-based therapeutics in COPD

Oxidative stress and macrophages: driving forces behind exacerbation of asthma and chronic obstructive pulmonary disease?

Understanding the role of neutrophils in chronic inflammatory airway disease

Phamacological strategies to regain steroid sensitivity in severe asthma and COPD

Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy

Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology

Angiotensins as therapeutic targets beyond heart disease

Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary disease

Local and systemic effects of angiotensin receptor blockade in an emphysema mouse model

Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice

Angiotensin-converting inhibitors and angiotensin II receptor blockers and longitudinal change in percent emphysema on computed tomogaphy

The association of renin-angiotensin system blockades and pneumonia requiring admission in patients with COPD

Effect of angiotensin 2 receptor blockers on chronic obstructive lung disease mortality: a retrospective cohort study

Oral formulation of angiotensin-(1-7) therapy attenuates pulmonary and systemic damage in mice with emphysema induced by elastase

Angiotensin-(1-7)-mediated Mas1 receptor/NF-B-p65 signaling is involved in a cigarette smoke-induced chronic obstructive pulmonary disease mouse model

Angiotensin-(1-7) attenuated cigarette smoking-related pulmonary fibrosis via improving the impaired autophagy caused by nicotinamide adenine dinucleotide phosphate reduced oxidase 4-dependent reactive oxygen species

Small-molecule AT2 receptor agonists

Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors

Evolution of angiotensin peptides and peptidomimetics as angiotensin II receptor type 2 (AT2) receptor agonists

The selective angiotensin II type 2 receptor agonist, compound 21, attenuates the progression of lung fibrosis and pulmonary J o u r n a l P r e -p r o o f hypertension in an experimental model of bleomycin-induced lung injury

Successful completion of a phase I, randomized, double-blind, placebo controlled, single ascending dose trial for the first in class angtiotensin AT2-receptor agonist compound 21

Vitamin E isoform γ-tocotrienol protects against emphysema in cigarette smoke-induced COPD, Free Radic

Ribosomal protein S3 gene silencing protects against cigarette smoke-induced acute lung injury

Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis

Tobacco smoking increaseses the lung gene expression of ACE2, the receptor of SARS-CoV-2

ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19

Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACEs in the respiratory tract

Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumtoid arthritis synovium

A possible anti-inflammatory role of angiotensin II type 2 receptor in immune-mediated glomerulonephritis during type 1 receptor blockade

Up-regulation of angiotensin II type 2 receptor in rat thoracic aorta by pressure-overload

Angiotensin-II-induced apoptosis requires regulation of nucleolin and Bcl-xL by SHP-2 in primary lung endothelial cells

Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison

Anti-fibrotic potential of AT2 receptor agonists

Matrix metalloproteinases in COPD

Role of proteases in chronic obstructive pulmonary disease

Increased collagen deposition correlated with lung destruction in human emphysema

Increased matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio in smokers with airway hyperresponsiveness and accelerated lung function decline

Attenuation of ligand-induced activation of angiotensin II type 1 receptor signaling by the type 2 receptor via protein kinase C

Evidence for heterodimerization and functional interaction of the angiotensin type 2 receptor and the receptor MAS

Atypical signaling and functional desensitization response of MAS receptor to peptide ligands

Dimerization of AT 2 and Mas receptors in control of blood pressure

G-protein-coupled receptor Mas is a physiological antagonist of angiotensin II type 1 receptor